Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Malaysia ETF (EWM) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI Malaysia ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Malaysia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.07, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EWMFLNA
Sector
Broad Market / FactorHealth
52-Week High
$30.42$4.64
52-Week Low
$24.73$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Malaysia ETF

EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.

Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA